Record and track on the go! Our customizable mobile app lets you track your injections instantly and efficiently with your iPhone®, iPod touch®, iPad®, or Android™ device.

A A A
Share, Send, or Save logo

Teva's COPAXONE®

Feel confident about your therapy choice

Many in the relapsing MS community have trusted in Teva's COPAXONE® (glatiramer acetate injection) since its approval in 1996. This trust has been built on its proven effectiveness and demonstrated safety profile across 5 clinical studies. You can count on the proven clinical profile of Teva's COPAXONE® with a 3-times-a-week dosing schedule. Injections must be at least 48 hours apart.

Image of COPAXONE® clinical studies timeline, proven across five clinical studies

Experience 3-times-a-week COPAXONE® 40 mg

  • The therapy you know and trust—in a 3-times-a-week dose
  • Injections must be at least 48 hours apart
  • Proven clinically effective1
  • Demonstrated safety and tolerability profile1
  • Teva's Shared Solutions® network of personalized support

3-times-a-week COPAXONE® 40 mg prescribed in the United States

Be Bold. Be True. Be You. Managing your relapsing MS Be Bold. Be True. Be You. Managing your relapsing MS

3-times-a-week COPAXONE® 40 mg offers a demonstrated safety profile

When you choose a relapsing MS therapy, you want it to be one that you can trust. 3-times-a-week COPAXONE® 40 mg offers you a demonstrated safety profile, with no known significant drug interactions. With 3-times-a-week COPAXONE® 40 mg, you can feel confident in your decision to stay committed to your relapsing MS therapy.

Drug interactions

Although not fully studied, COPAXONE® has not demonstrated any significant interactions with medications commonly used in MS patients.

  • This includes combination use with corticosteroids (up to 28 days)
  • COPAXONE® has not been formally evaluated in combination with interferon beta

COPAXONE® is Pregnancy Category B

Animal studies have failed to demonstrate a risk to the fetus, and there are no adequate and well-controlled studies in pregnant women.

Because animal reproduction studies are not always predictive of human response, COPAXONE® should be used in pregnancy only if clearly needed.

If you are pregnant or planning to become pregnant, let your doctor know.

If you are changing to 3-times-a-week COPAXONE® 40 mg from another therapy, be sure to follow the advice of your doctor. It is highly recommended that you schedule free, in-home, 1-on-1 injection training with a Shared Solutions® nurse before starting 3-times-a-week COPAXONE® 40 mg.

Hear why doctors are prescribing 3-times-a-week COPAXONE® 40 mg.
Doctors in the video have been compensated by Teva.

 

back to top

TALK TO YOUR DOCTOR

Make the move to 3-times-a-week COPAXONE® 40 mg.

SEE PATIENT PERSPECTIVES

Learn why Melissa* attends MS educational events and how you can sign up for one today.

*Has been compensated by Teva